SEC Comment Letter 0000000000-25-003930 to MAINZ BIOMED N.V. (MYNZ) (CIK 0001874252) (MYNZ)
MAINZ BIOMED N.V. (MYNZ) (CIK 0001874252)
Date: April 14, 2025 · CIK: 0001874252 · Accession: 0000000000-25-003930
AI Filing Summary & Sentiment
Reasoning
Letter
Re: Mainz Biomed N.V. Draft Registration Statement on Form F-1 Submitted April 9, 2025 CIK No. 0001874252 Dear Guido Baechler:
April 14, 2025
Guido Baechler Chief Executive Officer Mainz Biomed N.V. Robert Koch Strasse 50 55129 Mainz Germany
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Tim Dockery
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 14, 2025 Guido Baechler Chief Executive Officer Mainz Biomed N.V. Robert Koch Strasse 50 55129 Mainz Germany Re: Mainz Biomed N.V. Draft Registration Statement on Form F-1 Submitted April 9, 2025 CIK No. 0001874252 Dear Guido Baechler: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Tim Dockery </TEXT> </DOCUMENT>